Dosing regimens

Patent metadata

Field	Value
Publication number	US-12528836-B2
Application number	US-202318392545-A
Country	US
Kind code	B2
Filing date	Dec 21, 2023
Priority date	Oct 7, 2015
Publication date	Jan 20, 2026
Grant date	Jan 20, 2026

Abstract

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

First claim

We claim:

1 . A method of administering a long-acting compstatin analog (LACA) to a human subject, the method comprising administering a dose of said LACA to an eye of the subject by intravitreal injection, wherein the amount of said dose is between about 15 mg and 20 mg, wherein the LACA comprises two compstatin analog moieties, wherein each compstatin analog moiety comprises a cyclic peptide having an amino acid sequence as set forth in SEO ID NO: 28, wherein the LACA has the structure:

and wherein the n results in a PEG having an average molecular weight of about 40kD.

2 . The method of claim 1 , wherein the amount of said dose is about 15 mg.

3 . The method of claim 1 , wherein the dose comprises the LACA at a concentration of from about 100 to about 200 mg/mL.

4 . The method of claim 3 , wherein the dose comprises the LACA at a concentration of about 150 mg/mL.

5 . The method of claim 2 , wherein the dose comprises the LACA at a concentration of about 150 mg/mL in a volume of 100 microliters.

6 . The method of claim 5 , wherein the dose is administered using a thin wall needle.

7 . The method of claim 6 , wherein the dose is administered using a 29 gauge thin wall needle.

8 . The method of claim 6 , wherein the dose is administered using a 27 gauge needle.

9 . The method of claim 1 , comprising administering a composition comprising the dose of said LACA, wherein the composition further comprises a pharmaceutically acceptable carrier.

10 . The method of claim 9 , wherein the pharmaceutically acceptable carrier is water.

Assignees

• Apellis Pharmaceuticals Inc

Inventors

• Grossi Federico
• Deschatelets Pascal
• Francois Cedric

Classifications

• A61P27/02

  Ophthalmic agents · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K47/595

  Polyamides, e.g. nylon (polyamino acids A61K47/62) · CPC title

• A61K47/60

  the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title